Antibiotic-resistant H. pylori
Helicobacter pylori colonizes the stomach of roughly half the world's population and is a class I carcinogen, causing peptic ulcer disease, MALT lymphoma, and gastric adenocarcinoma. Standard triple and quadruple eradication regimens are failing at increasing rates because of surging resistance to clarithromycin, metronidazole, and levofloxacin, leading the WHO to list clarithromycin-resistant H. pylori as a high-priority pathogen for new therapies. Bacteriophages are attractive here because they kill in a strain-specific manner that spares the surrounding gastric and gut microbiota, can self-amplify at the infection site, and act through mechanisms entirely independent of the antibiotic targets driving resistance. This makes them a candidate alternative or adjunct precisely for the multidrug-resistant strains where conventional eradication breaks down.
How phages act here
Mechanism
Phages adsorb to surface receptors on specific H. pylori strains and, for lytic phages, hijack the host to replicate and burst the cell; this strain specificity is both an asset (microbiome-sparing) and a hurdle given H. pylori's extreme genetic diversity, so cocktails of multiple phages are proposed to broaden coverage. A central, well-documented challenge is that almost no strictly virulent (obligately lytic) H. pylori phages have been isolated; most known H. pylori phages are temperate/prophages (carried in roughly 25-30% of genomes), so research focuses on prophage induction (e.g., UV) and genome mining to recover usable phages. Because the niche is the acidic, mucus-covered gastric epithelium and biofilm, candidate phages and phage-derived products must survive low pH and penetrate mucus; phage-antibiotic synergy is being explored to resensitize resistant strains and reduce dosing. To bypass the lytic-phage shortage, the field is pivoting to engineered approaches: AI-assisted endolysin/"artilysin" discovery to enzymatically degrade peptidoglycan, receptor-binding-protein engineering to expand host range, CRISPR-Cas-armed phage payloads, and targeted gastric delivery platforms to stabilize and localize activity.
Where it stands
Current evidence
As of 2026, evidence is preclinical and exploratory — there are no completed or registered human clinical trials of phage therapy for H. pylori, and no approved product. Work is concentrated in in vitro characterization and genomics: for example, the temperate podovirus HPy1R was induced from a clinical strain (UV induction), shown to be stable across pH 3-11 and through a simulated gastric digestion model, and able to suppress H. pylori for up to 24 h, positioning it as a candidate 'in the absence of strictly lytic phages' (Ferreira et al., 2022). Other groups have screened panels of clinical strains by PCR and whole-genome sequencing to catalog inducible intact prophages as a therapeutic reservoir (Ferreira et al., 2024), and prophage genomics across the 1,011-genome H. pylori Genome Project produced the first lysogeny/lytic-cycle regulation model (Vale et al., 2024). The most recent 2025-2026 reviews frame the realistic near-term path as engineered/phage-derived strategies — endolysins, host-range engineering, and gastric delivery systems — rather than classical whole-phage therapy, while emphasizing that in vivo efficacy, biosafety, and functional validation are still outstanding (Li et al., 2026; Hanafiah et al., 2025).
Evidence confidence: low
The data
Key studies & trials
- Li Z, Chen L, Huang S, et al. Helicobacter pylori phages: resource landscape, translational challenges, and engineered antibacterial strategies. Archives of Microbiology. 2026;208(9):441. ↗
- Ferreira R, Sousa C, Gonçalves RFS, et al. Characterization and Genomic Analysis of a New Phage Infecting Helicobacter pylori. International Journal of Molecular Sciences. 2022;23(14):7885. ↗
- Ferreira R, Pinto G, Presa E, et al. Screening and in silico characterization of prophages in Helicobacter pylori clinical strains. Microbes and Infection. 2024;27(3):105429. ↗
- Vale FF, Roberts RJ, Kobayashi I, Camargo MC, Rabkin CS. Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the Helicobacter pylori Genome Project. Gut Microbes. 2024;16(1):2379440. ↗
Who is working on it
Programs & centers
The possibility
If genome-mined prophages and AI-designed endolysins can be turned into acid-stable, mucus-penetrating cocktails, a future eradication course might be a swallowed phage or 'artilysin' preparation that wipes out a patient's specific resistant strain while leaving the rest of the gut flora untouched — a precision counterpoint to today's broad-spectrum antibiotic blasts. Engineered receptor-binding proteins and CRISPR-armed payloads could even let a single tailored construct cover the diversity of strains seen across a population, or resensitize stubborn biofilms so a lower antibiotic dose finishes the job. The likeliest first clinical win is a phage-derived enzyme or phage-antibiotic adjunct rather than classical whole-phage therapy, given how few naturally lytic H. pylori phages exist.